Tage Honore - 08 Jun 2023 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Reporting relationship: Director
Issuer ticker: VNDA
Reported as of: 08 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2023, 16:19:01 UTC
Prior SEC filing: 17 Mar 2023
Next SEC filing: 21 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Tage Honore

Key filing fact

Tage Honore filed Form 4 for Vanda Pharmaceuticals Inc. (VNDA) on 12 Jun 2023.

Key facts

This page summarizes Tage Honore's Form 4 filing for Vanda Pharmaceuticals Inc. (VNDA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2023, 16:19.

Change

Previous filing in this sequence was filed on 17 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VNDA transaction

Common Stock

Award

Transaction value: $0
Shares: +17,307
Change %: +66%
Price: $0.000000
Shares after: 43,715
Date: 08 Jun 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VNDA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +33,960
Change %
Price: $0.000000
Shares after: 33,960
Date: 08 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,960
Exercise price: $6.50
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.

Footnote F2

This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.